Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.

Herman M; Okoji O; Castaneda D; Jirru E; Kotler D

doi:10.1111/apt.13836

Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.

Herman M, Okoji O, Castaneda D, Jirru E, Kotler D

MeSH — NLM indexing Aspartate Aminotransferases Hepacivirus Hepatitis C Humans Liver Cirrhosis Platelet Count

Actions du personnel

Télécharger le PDF

Les fichiers sont réservés à un usage autorisé dans les canaux partenaires BioPredictive.

Fibrotest Actitest Letter Independent Group United States

Auteurs (5)

Herman M — Department of Medicine, Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA.
Okoji O — Department of Medicine, Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA.
Castaneda D — Department of Medicine, Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA.
Jirru E — Department of Medicine, Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA.
Kotler D — Department of Medicine, Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA.

Citation

Herman M, Okoji O, Castaneda D, Jirru E, Kotler D. Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients. Aliment Pharmacol Ther. 2017;45(1):190-191. doi:10.1111/apt.13836.

Identifiants

DOI: 10.1111/apt.13836
PMID: 27910146

Tests

Maladies du foie

Atteintes hépatiques

Comparaisons

Thèmes

Région

Panier

Votre panier est vide.

Parcourez les publications et utilisez Ajouter au panier sur n'importe quelle page de détail pour constituer une archive ZIP à envoyer aux clients.

Parcourir les publications

Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.

Sur le même sujet

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Noninvasive Assessment of Liver Fibrosis.

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Toward non-invasive assessment strategies in autoimmune hepatitis.